Table 4.
Overall duration of response, time to progression and overall survival with bortezomib treatment in patients with relapsed/refractory multiple myeloma (efficacy analysis set)
| Time (days) | Patients maintaining response, % (SE) | 95% CI |
|---|---|---|
| Duration of response | ||
| 30 | 88.3 (1.7) | 84.5, 91.2 |
| 60 | 83.4 (2.2) | 78.6, 87.3 |
| 120 | 81.6 (2.4) | 76.3, 85.8 |
| 240 | 72.5 (3.6) | 64.8, 78.8 |
| 360 | 59.9 (6.1) | 46.8, 70.7 |
| 480 | 55.3 (7.2) | 40.2, 68.0 |
| 600 | 55.3 (7.2) | 40.2, 68.0 |
| 720 | 0.0 (0.0) | – |
| Time to progression | ||
| 30 | 2.1 (0.7) | 1.1, 4.1 |
| 60 | 6.9 (1.3) | 4.7, 10.1 |
| 120 | 16.1 (2.3) | 12.2, 21.2 |
| 240 | 24.1 (3.2) | 18.5, 31.1 |
| 360 | 35.9 (5.4) | 26.4, 47.4 |
| 480 | 59.3 (9.6) | 41.6, 77.7 |
| 600 | 59.3 (9.6) | 41.6, 77.7 |
| 720 | 100.0 (0.0) | – |
| Overall survival | ||
| 30 | 97.2 (0.8) | 95.1, 98.3 |
| 60 | 94.1 (1.2) | 91.3, 96.0 |
| 120 | 89.1 (1.8) | 85.0, 92.1 |
| 240 | 79.0 (2.9) | 72.5, 84.1 |
| 360 | 66.6 (4.5) | 57.1, 74.5 |
| 480 | 49.9 (6.6) | 36.5, 62.0 |
| 600 | 35.3 (7.7) | 20.7, 50.2 |
| 720 | 25.2 (8.2) | 11.2, 42.0 |
| Quantile and 95% CI of time to progression | |
|---|---|
| Quantile (%) | 95% CI |
| 75 | 705.0 (429.00, 705.00) |
| 50 | 415.0 (382.00, 705.00) |
| 25 | 268.0 (186.00, 354.00) |
Efficacy analysis set: included patients who received at least 1 dose of bortezomib (with 1 or more prior treatments)
CI confidence interval, SE standard error